VANCOUVER, Oct. 18 /CNW/ - Protox Therapeutics Inc. (TSX-V:PRX), a leader
in advancing novel, targeted protein toxin therapeutics for the treatment of
cancer and other proliferative diseases, today announced that the U.S. Patent
and Trademark Office has issued U.S. Patent 7,282,476 covering the composition
of PRX302, the Company's lead drug candidate from its PORxin(TM) technology
platform, and its use for the treatment of prostate cancer. Additional claims
were issued which protect other modified proaerolysin variants targeting
prostate cancer. The patent was issued to the University of Victoria
Innovation and Development Corporation and Johns Hopkins University and is
licensed to Protox on an exclusive worldwide basis.
